HCW Biologics Inc. (HCWB) NASDAQ
1.68
-0.11(-6.15%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.68
-0.11(-6.15%)
Currency In USD
| Previous Close | 1.79 |
| Open | 1.77 |
| Day High | 1.78 |
| Day Low | 1.57 |
| 52-Week High | 7.35 |
| 52-Week Low | 0.25 |
| Volume | 1.2M |
| Average Volume | 20.31M |
| Market Cap | 3.5M |
| PE | -0.2 |
| EPS | -8.29 |
| Moving Average 50 Days | 0.77 |
| Moving Average 200 Days | 2.04 |
| Change | -0.11 |
HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter
GlobeNewswire Inc.
Mar 02, 2026 1:00 PM GMT
MIRAMAR, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (Nasdaq: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by
HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
GlobeNewswire Inc.
Feb 18, 2026 2:50 AM GMT
MIRAMAR, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend health span by tar
HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune
GlobeNewswire Inc.
Feb 13, 2026 1:30 PM GMT
HCW Biologics receiving cash fee and co-founder shares in Trimmunevalued at $7.0 million Trimmune will hold exclusive worldwide license for rights to high potential preclinical molecule created with HCW Biologics’ TRBC drug development platform Initi